Drug
Mp0250 Darpin Drug Candidate
Mp0250 Darpin Drug Candidate: highest development phase Phase 1, developed by Molecular Partners. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Molecular Partners
Trials
| Drug | Phase | Indication |
|---|---|---|
| MP0250 DARPin® drug candidate, Osimertinib NCT03418532 | Phase 1 | EGFR-mutated NSCLC (Disorder) |
Latest
No recent events.
Follow Mp0250 Darpin Drug Candidate on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.